Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report)’s stock price dropped 5% during mid-day trading on Tuesday . The company traded as low as $16.50 and last traded at $16.67. Approximately 18,174 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 209,996 shares. The stock had previously closed at $17.54.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Friday, September 20th.
View Our Latest Analysis on PLSE
Pulse Biosciences Stock Performance
Institutional Investors Weigh In On Pulse Biosciences
Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after buying an additional 189,227 shares during the last quarter. Griffin Asset Management Inc. increased its holdings in shares of Pulse Biosciences by 15.7% during the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock worth $2,616,000 after acquiring an additional 40,700 shares during the last quarter. Westside Investment Management Inc. raised its stake in Pulse Biosciences by 97.8% in the 2nd quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after acquiring an additional 31,440 shares during the period. Bank of New York Mellon Corp lifted its holdings in Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after purchasing an additional 9,639 shares during the last quarter. Finally, Inspire Investing LLC boosted its position in Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock worth $360,000 after purchasing an additional 10,039 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
- Five stocks we like better than Pulse Biosciences
- How to Calculate Inflation Rate
- Why Lennar Stock Could Be the Best Play in the Housing Market
- The How And Why of Investing in Oil Stocks
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.